[Ad hoc announcement pursuant to Art. 53 LR] Roche reports …

4 days ago · Roche’s wholly owned subsidiary Blue Giant Acquisition Corp. accepted for payment all shares validly tendered and not validly withdrawn pursuant to its tender offer for all …

CouponFollow Extension

7%
OFF

[Ad Hoc Announcement Pursuant To Art. 53 LR] Roche Reports …

3 weeks from now

4 days ago · [Ad hoc announcement pursuant to Art. 53 LR] Roche reports strong 2024 results with 7% sales growth; fourth quarter marks third straight quarter of 9% growth F. Hoffmann-La …

yahoo.com

1%
OFF

[Ad Hoc Announcement Pursuant To Art. 53 LR] Roche Exceeds

3 weeks from now

Feb 1, 2024 · [Ad hoc announcement pursuant to Art. 53 LR] Roche exceeds guidance and achieves sales growth of 1% (CER) for 2023 despite sharp COVID-19 sales decline Published …

nasdaq.com

7%
OFF

[Ad Hoc Announcement Pursuant To Art. 53 LR] Roche Reports …

3 weeks from now

[Ad hoc announcement pursuant to Art. 53 LR] Roche reports strong 2024 results with 7% sales growth; fourth quarter marks third straight quarter of 9% growth ... Roche announces new …

ft.com

7%
OFF

GNW-News: [Ad-hoc-Mitteilung Gemäss Art. 53 KR] Roche Erzielt …

3 weeks from now

4 days ago · GNW-News: [Ad-hoc-Mitteilung gemäss Art. 53 KR] Roche erzielt starkes Jahresergebnis für 2024 mit Verkaufswachstum von 7%; drittes Quartal in Folge mit 9% …

boerse.de

7%
OFF

[Ad Hoc Announcement Pursuant To Art. 53 LR] Roche Reports …

3 weeks from now

4 days ago · [Ad hoc announcement pursuant to Art. 53 LR] Roche reports strong 2024 results with 7% sales growth; fourth quarter marks third straight quarter of 9% growth January 30, …

marketscreener.com

FAQs about [Ad hoc announcement pursuant to Art. 53 LR] Roche reports … Coupon?

How did the repurchase of Roche shares impact Novartis?

This includes the positive impact of the repurchase of Roche shares held by Novartis. Sales in the Pharmaceuticals Division increased by 2% to CHF 45.6 billion. Newer medicines to treat severe diseases continued their strong growth. Vabysmo, an eye medicine launched at the beginning of 2022, is already one of the top five growth drivers. ...

How did Roche perform in 2022?

In 2022, Roche achieved sales growth of 2% (+1% in CHF) to CHF 63.3 billion. Core operating profit increased by 3% (+1% in CHF), reflecting the good underlying business performance. IFRS net income was CHF 13.5 billion, a decrease of 6% compared to the previous year. ...

How did Roche perform in the first quarter?

Roche CEO Thomas Schinecker: “We saw strong growth in the first quarter in both divisions’ base business, which largely compensated for the expected drop in sales of COVID-19 tests. We made progress in our pipeline in the first quarter, especially in blood cancer. ...

Is Roche's earnings per share growth a profit forecast?

The statement regarding earnings per share growth is not a profit forecast and should not be interpreted to mean that Roche’s earnings or earnings per share for this or any subsequent period will necessarily match or exceed the historical published earnings or earnings per share of Roche. 3. ...

Why did Roche become a world leader in in-vitro diagnostics?

This was mainly due to growth in the advanced staining business. Founded in 1896 in Basel, Switzerland, as one of the first industrial manufacturers of branded medicines, Roche has grown into the world’s largest biotechnology company and the global leader in in-vitro diagnostics. ...